NRXS
NeurAxis, Inc.
There isn't enough reported data to score NRXS yet.
NRXS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Unavailable | |
| Unavailable |
NRXS's revenue is currently strong, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
NRXS PE Valuation
NRXS has no meaningful PE right now: it lost money over the past year.
NRXS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect NRXS's losses to shrink, with revenue growing.
NRXS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.05 | -$0.03 |
| Q2 2026 | -$0.77 | +$0.26 |
| Q1 2026 | -$0.80 | +$0.43 |
| Q4 2025 | -$0.95 | +$0.27 |
| Q3 2023 | -$2.91 | -$2.22 |
NRXS is still losing money, but far less than before: $1.05 per share over the past year, against $2.91 at its worst in late 2023.
NRXS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2M | +150% |
| Q2 2026 | $1.9M | +116% |
| Q1 2026 | $1.6M | +80% |
| Q4 2025 | $968.1K | +27% |
| Q3 2025 | $811.4K | +22% |
| Q2 2025 | $894.1K | +46% |
| Q1 2025 | $895.7K | +39% |
| Q4 2024 | $761.2K | +43% |
NRXS's revenue has grown year over year for nine quarters in a row: $2M last quarter, up 150% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -324% | -66 points |
| Q2 2026 | -110% | +82 points |
| Q1 2026 | -108% | +148 points |
| Q4 2025 | -177% | +15 points |
| Q3 2025 | -259% | -11 points |
| Q2 2025 | -192% | +169 points |
| Q1 2025 | -256% | +27 points |
| Q4 2024 | -193% | +113 points |
NRXS's operating margin was −324% last quarter, down 66 points from the same quarter a year ago, near the bottom of its range since 2021.
NRXS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.3M | -$840.8K |
| Q4 2025 | -$1.9M | -$181.9K |
| Q3 2025 | -$1.4M | -$30.4K |
| Q2 2025 | -$1.5M | +$149K |
| Q1 2025 | -$1.6M | -$274.8K |
| Q4 2024 | -$1.8M | +$887.4K |
| Q3 2024 | -$1.4M | +$1.4M |
| Q1 2024 | -$1.3M | -$716.4K |
NRXS has burned cash in almost every quarter: −$7M over the past year, against −$6M the year before.
NRXS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.1% | +865K shares |
| 1 year | +31% | +3.1M shares |
| 3 years | +548% | +11M shares |
NRXS has 13M diluted shares, up 31% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
NRXS Net Leverage
NRXS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NRXS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.3 | Neutral |
| Stochastic | 38.7 | Neutral |
NRXS's weekly RSI is 42 (neutral) and its Stochastic is 39 (neutral).
NRXS PE vs Healthcare Sector
NRXS has no meaningful PE right now: it lost money over the past year.
NRXS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.98 | 18% below |
| 20 week MA | $6.73 | 15% below |
| 50 week MA | $6.28 | 8.4% below |
| 100 week MA | $4.39 | 31% above |
NRXS has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 31% above its 100-week average.
NRXS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $6.15 | $2.67 | -57% |
| 2024 | $2.67 | $2.43 | -9% |
| 2025 | $2.43 | $3.92 | +61% |
| 2026 YTD | $3.92 | $5.75 | +47% |
NRXS is up 47% so far in 2026, after finishing lower in two of the previous three years.